Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 9:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 4,592 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Crossover Clear all
Completed Phase 1 Interventional Results available

Relative Bioavailability of Pimasertib in Cancer Patients

NCT01992874
View directory record Official record
Conditions
Neoplasms
Interventions
Pimasertib Capsule (Part A), Pimasertib Tablet (Part A), Pimasertib Capsule (Part B and trial extension phase)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants

NCT02220218
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC), Canagliflozin, Metformin IR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dinner Time 2: Effect of Delayed Eating or Sleeping on Metabolism

NCT04671797
View directory record Official record
Conditions
Healthy
Interventions
Early dinner, Late Dinner, Late Dinner + Late Sleep
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 30 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects

NCT04587713
View directory record Official record
Conditions
Intestinal Disorder, Bowel Diseases, Inflammatory
Interventions
TD-1473 [Tablet A], TD-1473 [Tablet B]
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Cypress, California • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Desloratadine and Pseudoephedrine Extended-release Tablets Under Fed Conditions

NCT01506791
View directory record Official record
Conditions
Healthy
Interventions
Desloratadine and pseudoephedrine
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Broadway, Florida
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Oct 27, 2026, 9:05 PM EDT
Terminated Phase 2 Interventional Results available

IVIG Treatment for Refractory Immune-Related Adult Epilepsy

NCT01545518
View directory record Official record
Conditions
Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System, Limbic Encephalitis
Interventions
IVIG
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2014 · Synced Oct 27, 2026, 9:05 PM EDT
Recruiting Phase 1 Interventional

Adia Med of Winter Park LLC Chronic Kidney Disease Research Study

NCT07572890
View directory record Official record
Conditions
Chronic Kidney Disease, Kidney Disease, Kidney Disease, Chronic, Chronic Kidney Disease (CKD), CKD
Interventions
Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione IV, Glutathione Spray, Placebo IV, Placebo Glutathione IV, Placebo Spray
Biological · Drug · Other
Lead sponsor
Adia Med of Winter Park LLC
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 27, 2026, 9:05 PM EDT
Completed No phase listed Observational Results available

A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors

NCT01131104
View directory record Official record
Conditions
Nonarteritic Anterior Ischemic Optic Neuropathy
Interventions
PDE5 Inhibitors
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
44
States / cities
Birmingham, Alabama • Los Altos, California • National City, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lycopene in Healthy Male Participants

NCT00450957
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Prostate Cancer
Interventions
lycopene, pharmacological study
Dietary Supplement · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

NCT05844787
View directory record Official record
Conditions
Parkinson's Disease
Interventions
MT101-5
Drug
Lead sponsor
Mthera Pharma Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Phase 2 Seattle Dietary Biomarkers Development Center

NCT06656338
View directory record Official record
Conditions
Healthy Adults
Interventions
Higher HEI-2020 diet followed by lower HEI-2020 diet, Lower HEI-2020 diet followed by higher HEI-2020 diet
Other
Lead sponsor
Marian Neuhouser
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Compensation With Substitution of Meat Products With White Button Mushrooms.

NCT00198770
View directory record Official record
Conditions
Obesity
Interventions
dietary substitution to assess level of caloric compensation
Dietary Supplement
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 27, 2026, 9:05 PM EDT
Withdrawn Phase 3 Interventional

A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals

NCT02242656
View directory record Official record
Conditions
Short Bowel Syndrome, Short Gut Syndrome, SBS, Short Bowel, Short Gut
Interventions
Opium Tincture USP Deodorized
Drug
Lead sponsor
Marathon Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT01912456
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
Low-volume C1-esterase inhibitor, Higher-volume C1-esterase inhibitor, Low-volume placebo, Higher-volume placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bell Gardens, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects

NCT01507610
View directory record Official record
Conditions
Migraine
Interventions
Sumatriptan
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Appetite Hormone Response of Proprietary Beverages

NCT06966570
View directory record Official record
Conditions
Healthy
Interventions
Study Product A: Mixed-macronutrient beverage, Study Product B: Single-macronutrient beverage
Other
Lead sponsor
Shaklee Corporation
Industry
Eligibility
20 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Phase 1 Interventional

Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients

NCT01750905
View directory record Official record
Conditions
Left Ventricular Insufficiency
Interventions
CD-NP, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia

NCT03783910
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
GRT9906, Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
DeLand, Florida • Charlotte, North Carolina • Medford, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 27, 2026, 9:05 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder

NCT03141086
View directory record Official record
Conditions
Circadian Rhythm Disorders
Interventions
LML134, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

NCT05337254
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 27, 2026, 9:05 PM EDT
Active, not recruiting Phase 1 Interventional

A Novel, Comprehensive Approach to Post-stroke Gait Rehabilitation

NCT04411303
View directory record Official record
Conditions
CVA (Cerebrovascular Accident)
Interventions
Step length biofeedback, Propulsive force biofeedback, Interlimb asymmetry biofeedback, Aerobic intensity-based walking
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Phase 1 Interventional

A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis

NCT00676156
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
oral lipoic acid (LA), lipoic acid (LA) with fish oil and LA without fish oil, R lipoic acid
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Phase 1Phase 2 Interventional

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

NCT03910660
View directory record Official record
Conditions
Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma
Interventions
BXCL701 plus Pembrolizumab, BXCL701 monotherapy
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 27, 2026, 9:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers

NCT04617782
View directory record Official record
Conditions
Healthy Subjects
Interventions
Donepezil TDS, Aricept
Combination Product · Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 9:05 PM EDT